Outset Medical (NASDAQ:OM – Get Free Report) and Endonovo Therapeutics (OTCMKTS:ENDV – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Risk and Volatility
Outset Medical has a beta of 1.99, meaning that its stock price is 99% more volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of -1.41, meaning that its stock price is 241% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Outset Medical and Endonovo Therapeutics, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Outset Medical | 1 | 2 | 3 | 0 | 2.33 |
Endonovo Therapeutics | 0 | 0 | 0 | 0 | N/A |
Valuation & Earnings
This table compares Outset Medical and Endonovo Therapeutics’ revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Outset Medical | $130.38 million | 0.92 | -$172.80 million | ($3.50) | -0.66 |
Endonovo Therapeutics | $140,000.00 | 6.23 | -$18.48 million | N/A | N/A |
Endonovo Therapeutics has lower revenue, but higher earnings than Outset Medical.
Profitability
This table compares Outset Medical and Endonovo Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Outset Medical | -132.54% | -102.50% | -52.42% |
Endonovo Therapeutics | -1,717.21% | N/A | -408.63% |
Summary
Outset Medical beats Endonovo Therapeutics on 6 of the 9 factors compared between the two stocks.
About Outset Medical
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.